Catalog No.
Product Name
Application
Product Information
Citations
-
CDK Inhibitor
Tibremciclib is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting significant antineoplastic activity. By blocking CDK4 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. Tibremciclib is primarily utilized in cancer research and therapeutic applications, focusing on targeting tumors driven by aberrant CDK4 signaling. -
CDK8/19 Inhibitor
Senexin A hydrochloride is a selective inhibitor of cyclin-dependent kinases 8 and 19 (CDK8 and CDK19), with an IC50 of 280 nM for CDK8. It specifically targets and inhibits p21-induced transcription, while sparing other biological functions of p21. In addition, Senexin A hydrochloride effectively suppresses CMV-GFP induction and the p21 stimulatory activity of NF-κB-dependent promoters, making it a valuable tool for studying transcriptional regulation and cell signaling pathways. -
CDK Inhibitor
Cdc7-IN-7 is a potent inhibitor of the Cdc7 kinase, a serine-threonine protein kinase critical for the initiation of DNA replication during the cell cycle. By selectively targeting Cdc7, this compound demonstrates significant potential in inhibiting cellular proliferation and tumor growth. Research applications include studies on cell cycle regulation, cancer biology, and potential therapeutic strategies in oncology. -
CDK2 Inhibitor
QR-6401 is a selective macrocyclic inhibitor of cyclin-dependent kinase 2 (CDK2), demonstrating an IC50 of 0.37 nM for CDK2/E1 and exhibiting varying activity against other CDKs. This compound shows potent antitumor efficacy in an OVCAR3 ovarian cancer xenograft model. QR-6401 is valuable for research into cancer mechanisms and potential therapeutic approaches targeting CDK2. -
CDK7 Inhibitor
CDK7-IN-6 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound exhibits over 200-fold selectivity for CDK7 compared to CDK1, CDK2, and CDK5. CDK7-IN-6 is valuable for cancer research, providing a tool for investigating the role of CDK7 in cell cycle regulation and potential therapeutic strategies. -
CDK Inhibitor
AGM-130 is a selective cyclin-dependent kinase (CDK) inhibitor that interferes with cell cycle progression. It has demonstrated significant antitumor activity, making it a valuable tool for cancer research. This compound can be utilized in studies aimed at understanding CDK modulation and its potential therapeutic implications in oncology. -
CDK7 Inhibitor
CDK7-IN-16 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating potent activity with an IC50 range of 1 to 10 nM. This compound is primarily utilized in cancer research, particularly in studies focused on malignancies characterized by transcriptional dysregulation. Its ability to modulate CDK7 activity makes it a valuable tool for investigating therapeutic strategies in oncology. -
CDK8 Inhibitor
CDK8-IN-6 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with a Kd of 13 nM. This compound exhibits significant cytotoxic effects on various cancer cell lines, including MOLM-13, OCI-AML3, MV4-11, NRK, and H9c2, with IC50 values ranging from 7.5 to 25 µM. CDK8-IN-6 holds promise for advancing research in acute myeloid leukemia (AML) and related cancer studies, making it a valuable tool for investigating CDK8's role in tumorigenesis. -
CDK4/9 Inhibitor
CDK4/9-IN-1 is a selective dual inhibitor of cyclin-dependent kinases 4 and 9, exhibiting IC50 values of 23 nM for CDK4 and 12 nM for CDK9. This compound demonstrates significant potential in the study of cancer biology, particularly in elucidating the role of CDK4 and CDK9 in the cell cycle and transcription regulation. Researchers may utilize CDK4/9-IN-1 to investigate therapeutic strategies targeting these kinases in various cancer models. -
P25/CDK5 Inhibitor
DSS30 is a selective inhibitor of P25/CDK5, targeting the phosphorylation of amyloid precursor protein lyase 1 (BACEl). By inhibiting this phosphorylation, DSS30 effectively reduces the secretion of β-amyloid (Aβ), a key factor in the pathogenesis of Alzheimer's disease. This compound is valuable for research into neurodegenerative disorders and mechanisms underlying Aβ accumulation. -
CDK8 Inhibitor
CDK8-IN-17 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with an IC50 value of 9 nM. This compound regulates transcriptional control and has demonstrated significant potential in cancer research by modulating oncogenic pathways. CDK8-IN-17 is valuable for studies investigating the role of CDK8 in tumorigenesis and therapeutic applications targeting cellular proliferation. -
CDK9 Inhibitor
CDK9-IN-31 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell proliferation. By inhibiting CDK9, this compound demonstrates significant anti-cancer activity through the suppression of cancer cell growth. Its potential applications extend to cancer research, providing valuable insights into therapeutic strategies targeting transcriptional regulation in malignancies. -
CDK Inhibitor
CDK/HDAC-IN-1 is a potent inhibitor targeting cyclin-dependent kinases CDK2, CDK4, CDK6, and histone deacetylase 6 (HDAC6) with respective IC50 values of 60.9 ± 2.9 nM, 276 ± 22.3 nM, 27.2 ± 4.2 nM, and 128.6 ± 0.4 nM. This dual-action compound demonstrates significant biological activity in inhibiting cell cycle progression and modulating gene expression. CDK/HDAC-IN-1 is suitable for research applications exploring cancer biology, epigenetic regulation, and therapeutic strategies targeting CDK and HDAC pathways. -
CDK7 Inhibitor
CDK7-IN-10 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with an IC50 value of less than 100 nM. This compound effectively inhibits kinase activity, leading to reduced cell proliferation and the induction of apoptosis in various cell types. CDK7-IN-10 is valuable for research applications focused on cancer biology and therapeutic development targeting cell cycle regulation. -
CDK9 Inhibitor
CDK9-IN-38 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting IC50 values of 1.2 nM for the wild-type enzyme and 3.3 nM for the L156F mutant variant. This compound has demonstrated significant inhibitory effects on tumor growth in both in vitro and in vivo models. CDK9-IN-38 is a valuable tool for research into the regulation of transcriptional control and the therapeutic potential for cancer treatment. -
CDK4/6 Inhibitor
CDK4/6-IN-7 is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), with IC50 values of 1.58 nM and 4.09 nM, respectively. This orally active compound demonstrates significant biological activity, making it a valuable tool for investigating the role of CDK4/6 in various cancer models, particularly in breast cancer research. Its specificity and efficacy support studies aimed at understanding and targeting cell cycle progression in tumor cells. -
CDK4/6 Inhibitor
PF-06842874 is a selective inhibitor of CDK4 and CDK6, targeting the cyclin D1 and cyclin D3 complexes with Ki values of 62 nM and 130 nM, respectively. This compound demonstrates significant biological activity in the inhibition of cell proliferation, making it a valuable tool in cancer research and the study of pulmonary arterial hypertension. Its ability to modulate cell cycle progression positions PF-06842874 as an important reagent for investigating therapeutic strategies in oncological and vascular disease contexts. -
CDK7 Inhibitor
CDK7-IN-32 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7), a key regulator of cell cycle progression and transcriptional regulation. This compound effectively disrupts CDK7 activity, leading to decreased phosphorylation of its substrates and subsequent modulation of cellular proliferation and survival. CDK7-IN-32 is utilized in cancer research and studies investigating the role of CDK7 in transcriptional control and therapeutic resistance. -
CDK9 Inhibitor
CDK9-IN-28 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell cycle progression. This compound exhibits strong anti-proliferative effects, particularly in solid tumor models, making it valuable for cancer research. Additionally, CDK9-IN-28 serves as a target protein ligand for the synthesis of PROTACs, aiding in the development of innovative therapeutic strategies for targeting CDK9-dependent pathways. -
CDK1/CDK2 Inhibitor
LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2. This compound demonstrates significant biological activity in inhibiting cyclin-dependent kinases, making it a valuable tool for investigating cell cycle regulation. LZ9 has potential applications in research focused on colorectal cancer (CRC), aiding in the exploration of therapeutic strategies targeting this malignancy. -
CDK9 Inhibitor
CDK9-IN-49 is a potent inhibitor of Cyclin-dependent kinase 9 (CDK9) with an IC50 of 7.32 nM. This compound effectively suppresses the proliferation of various cancer cell lines, making it a valuable tool for cancer research. CDK9-IN-49 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, facilitating investigations into therapeutic strategies targeting CDK9 pathways. -
CDK4/6 Inhibitor
CDK4/6-IN-24 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), key regulators of the cell cycle. This compound demonstrates broad-spectrum antitumor activity across various cancer cell lines, with IC50 values in the submicromolar range. CDK4/6-IN-24 is a valuable tool for researchers investigating cell cycle regulation and therapeutic strategies for cancer treatment. -
CDK2 Inhibitor
CDK2-IN-54 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a critical regulator of the cell cycle. This compound demonstrates potent anti-proliferative activity in various cancer types, including triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer. CDK2-IN-54 is valuable for research applications focused on understanding cell cycle dynamics and exploring therapeutic strategies in oncology. -
CDK9 PROTAC Degrader
PROTAC CDK9 degrader-11 is an orally active PROTAC degrader that specifically targets CDK9, demonstrating a DC50 value of 1.09 nM. This compound shows cytotoxicity in various small cell lung cancer cell lines with an IC50 in the nanomolar range. PROTAC CDK9 degrader-11 effectively induces cell cycle arrest at the G0/G1 phase and reduces invasion in DMS114 and DMS53 cells. Additionally, it exhibits significant antitumor efficacy in NCI-H446 xenograft mouse models, making it a valuable tool for cancer research and therapeutic development. -
CDK4/6 Inhibitor
CDK4/6-IN-21 maleate is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting IC50 values of 3.88 nM and 3.31 nM against CDK4 and CDK6, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for research into cell cycle regulation and cancer therapeutics. Its targeted inhibition of CDK4/6 positions it as a key reagent for studying oncogenic pathways and developing new cancer treatment strategies. -
CDK4/CDK6 Inhibitor
CDK4/6-IN-20 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/CDK6), demonstrating IC50 values of 1.9 nM and 14.2 nM, respectively. This compound effectively inhibits cell proliferation, making it a valuable tool for cancer research applications. Its selective inhibition of CDK4/6 contributes to understanding cell cycle regulation and potential therapeutic interventions in malignancies. -
CDK Iinhibitor
CGP-79807 is a purine-based inhibitor targeting cyclin-dependent kinases (CDKs). It effectively disrupts the cell cycle by inhibiting CDK activity, leading to the suppression of tumor cell proliferation. This compound is valuable in cancer research for exploring the mechanisms of cell cycle regulation and potential therapeutic strategies. -
CDK2/4/6 Inhibitor
CDK2/4/6-IN-1 is a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, with IC50 values of 2.5 nM, 23.7 nM, and 44.3 nM, respectively. This compound is valuable for cancer research, allowing for the study of cell cycle regulation and tumor progression. Additionally, CDK2/4/6-IN-1 features an alkyne group enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, facilitating bioconjugation and labeling applications in chemical biology. -
CDK
[pThr3]-CDK5 Substrate is a specific substrate for cyclin-dependent kinase 5 (CDK5), functioning primarily through phosphorylation at threonine 3. This substrate is based on the histone H1 peptide sequence, which effectively binds within the active site of CDK5. It is phosphorylated by CDK5 with a Km value of 6 µM, making it useful for studies examining CDK5 activity and regulation in various biological contexts. -
CDK Inhibitor
CDK7-IN-22 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with demonstrated antitumor activity. Its inhibition of CDK7 plays a crucial role in modulating transcriptional regulation and cell cycle progression, making it a valuable tool for cancer research. CDK7-IN-22 is suitable for studies on tumorigenesis, therapeutic resistance, and cellular proliferation pathways. -
CDK7 Inhibitor
CDK7-IN-14 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), a key enzyme involved in transcriptional regulation and cell cycle progression. This pyrimidinyl derivative exhibits significant potential in cancer research, particularly in the study of tumors characterized by transcriptional dysregulation. CDK7-IN-14 may serve as a valuable tool for investigating therapeutic strategies targeting CDK7 in various malignancies. -
CDK Inhibitor
(+)-Atuveciclib is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) and the positive transcription elongation factor b (P-TEFb). With an IC50 value of 13 nM, it effectively suppresses CDK9 in cellular assays. This compound is primarily utilized in research related to transcription regulation and cancer therapeutics, offering insights into CDK9-mediated pathways and their role in various malignancies. -
CDKI Inhibitor
CDKI-IN-1 is a potent cyclin-dependent kinase inhibitor (CDKI) designed for investigating the role of CDK modulation in central nervous system (CNS) degenerative diseases. It effectively inhibits CDK activity, thereby providing insight into cell cycle regulation and neuronal cell survival. This compound is valuable for exploring therapeutic strategies targeting CDK pathways in neuroscience research. -
CDK4/6 Inhibitor
Crozbaciclib fumarate is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), with IC50 values of 3 nM and 1 nM, respectively. This compound effectively regulates cell cycle progression by hindering the phosphorylation of retinoblastoma protein, thereby halting proliferation in various cancer cell lines. Crozbaciclib fumarate is utilized in oncology research, particularly in studies investigating the therapeutic potential of targeting CDK4/6 in tumor growth and resistance mechanisms. -
PTEFb/CDK9 Inhibitor
BAY-1112054 hydrochloride is a potent inhibitor of PTEFb/CDK9, demonstrating high selectivity within the cyclin-dependent kinase family. This compound exhibits significant antiproliferative activity against various cancer cell lines, including HeLa and MOLM-13. BAY-1112054 hydrochloride is characterized by good metabolic stability and effectively suppresses tumor growth in mouse xenograft models while maintaining a favorable toxicity profile. Its mechanism and efficacy make it a valuable tool for cancer research applications. -
CDK4/6 PROTAC Degrader
CST651 is a selective proteolysis-targeting chimera (PROTAC) degrader specifically designed to target cyclin-dependent kinases CDK4 and CDK6. This compound effectively degrades CDK4 and CDK6 in MM.1S cells, exhibiting DC50 values of 20 nM and 5.1 nM, respectively. CST651 demonstrates the ability to inhibit cancer cell proliferation and migration, making it a valuable tool for research into various cancers, including acute lymphoblastic leukemia. -
CDK9 Inhibitor
SLM6 is a potent CDK9 inhibitor, specifically targeting the CDK9/cyclin K and CDK9/cyclin T1 complexes with IC50 values of 280 nM and 133 nM, respectively. In addition, SLM6 also effectively inhibits CDK1/cyclin B and CDK2/cyclin A, demonstrating IC50 values below 300 nM. This compound has been shown to induce apoptosis in multiple myeloma cells, making it a valuable tool for research in cancer biology and therapeutic development for hematological malignancies. -
CDK1/2 Inhibitor
Xylocydine is a potent inhibitor of cyclin-dependent kinases CDK1 and CDK2, demonstrating IC50 values of 1.4 nM and 61 nM, respectively. This compound effectively disrupts CDK activity, contributing to the regulation of apoptotic processes. Additionally, Xylocydine downregulates the levels of phosphorylated nucleolin and retinoblastoma protein, making it a valuable tool for investigations into cell cycle regulation and cancer research. -
CDK7 Inhibitor
CDK7-IN-18 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7). This pyrimidinyl derivative exhibits significant potential in the investigation of various cancers, particularly those associated with transcriptional dysregulation. CDK7-IN-18 serves as a valuable tool for research applications focused on understanding tumorigenesis and exploring therapeutic strategies targeting CDK7-mediated pathways. -
CDK2 Inhibitor
CDK2-IN-8 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 value of 1.74 µM. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studying cancer biology. CDK2-IN-8 is particularly relevant for research applications focused on melanoma and related malignancies, where CDK2 activity plays a crucial role in cell cycle regulation and tumor progression. -
CDK5 Inhibitor
CDK5-IN-2 is a highly selective cyclin-dependent kinase 5 (CDK5) inhibitor, exhibiting IC50 values of 0.2 nM against CDK5/p25 and 23 nM against CDK2/CycA. It serves as a valuable tool in research focused on neurodegenerative diseases, as CDK5 plays a critical role in neuronal function and development. This compound enables the exploration of CDK5's involvement in various cellular processes and its potential as a therapeutic target. -
CDK2 Degrader
CDK2 Degrader 8 is a novel chemical probe designed to target and degrade cyclin-dependent kinase 2 (CDK2). By specifically modulating CDK2 levels, it demonstrates significant anti-tumor activity, making it a valuable tool for investigating solid tumors such as breast cancer and ovarian serous cystadenocarcinoma, as well as liquid tumors like diffuse large B-cell lymphoma and acute myelogenous leukemia. CDK2 Degrader 8 facilitates research into the pathological roles of CDK2 dysregulation in cancer. -
CDK2 Inhibitor
TrkA Inhibitor is a selective CDK2 inhibitor, demonstrating an IC50 of 0.69 μM against CDK1. This compound is particularly valuable in research focused on chemotherapy-induced alopecia, allowing for the investigation of mechanisms involved in hair follicle cycling and potential therapeutic interventions. Its specificity for CDK2 makes it a useful tool in examining cell cycle regulation and associated pathways in various biological contexts. -
CDK9 Inhibitor
CDK9-IN-19 is a selective inhibitor of Cyclin-Dependent Kinase 9 (CDK9), exhibiting a potent IC50 value of 2.0 nM. This compound demonstrates significant antiproliferative activity in cellular assays and effectively suppresses tumor growth in MV4-11 xenograft models. With moderate pharmacokinetic properties and minimal hERG inhibition, CDK9-IN-19 is valuable for research on acute myeloid leukemia (AML) and related oncogenic pathways. -
CDK9 Inhibitor
CDK9-IN-22 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 of 10.4 nM for CDK9, demonstrating significant efficacy in disrupting cellular pathways. This compound is known to induce apoptosis and promote cell cycle arrest at the G2/M phase. Additionally, CDK9-IN-22 decreases the levels of phosphorylated RNA polymerase II (S2) and CDK9 protein, exhibiting notable antiproliferative and anti-tumor properties. It is a valuable tool for research in cancer biology and therapeutic applications targeting CDK9-related pathways. -
CDK Inhibitor
P18IN005 hydrochloride is a selective inhibitor of cyclin-dependent kinase (CDK), primarily targeting p18. This compound effectively regulates hematopoietic stem cell (HSC) self-renewal, demonstrating superior potency compared to p27 in mouse models. P18IN005 hydrochloride enhances the expansion of functional HSCs in short-term cultures, making it a valuable reagent for investigating the signaling pathways that govern stem cell self-renewal and differentiation processes. -
CDK4/6 Inhibitor
CDK4/6-IN-14 is a potent and highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), displaying IC50 values of 10 nM and 16 nM, respectively. This compound exhibits over 60-fold selectivity compared to CDK1, CDK2, CDK7, and CDK9, while demonstrating high specificity against a broader panel of 205 kinases. CDK4/6-IN-14 is valuable for research into cell cycle regulation and has potential applications in studying cancer therapeutics and targeted therapies. -
CDK9 Inhibitor
CDK9-IN-15 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcription elongation. By inhibiting CDK9, this compound effectively reduces the phosphorylation of RNA polymerase II, leading to decreased transcriptional activity of oncogenes. CDK9-IN-15 is primarily utilized in cancer research to explore therapeutic strategies that target transcriptional regulation in malignancies. -
CDK7 Inhibitor
CDK7-IN-13 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with a pyrimidinyl derivative structure. This compound exhibits significant activity against cancer cells characterized by transcriptional dysregulation, making it a valuable tool for cancer research. Its application in studies targeting CDK7 may enhance the understanding of cancer biology and aid in the development of novel therapeutic strategies. -
CDK9 Inhibitor
CDK9-IN-48 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), demonstrating an IC50 value of 1.37 nM. This compound effectively suppresses the proliferation of a variety of cancer cell lines, making it a valuable tool in cancer research. CDK9-IN-48 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, where targeting CDK9 may provide therapeutic benefits.
